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Detailed Statistical Methods: Estimation of “Usual” Blood Pressure 
 
To ensure natural blood pressure variation and any measurement error was accounted for, a 
standard correction for such regression-dilution bias was made. (Supplemental Figure 2).1,2 
Each individual's usual systolic blood pressure, S, was estimated using linear regression 
models with blood pressure at the study midpoint (2.5 years) as the outcome and their 
baseline value, s, as the explanatory variable. It was found that there was a quadratic 
relationship between baseline and follow-up blood pressure, so usual systolic blood pressure 
was estimated using the formula: 
 
S=136.1 + 0.316(s - 138.9) - 0.001(s - 138.9)2. 
 
Similarly, each individual's usual diastolic blood pressure, D, was calculated from their 
baseline value, d, using the formula:  
 
D=77.1 + 0.396(d - 79.1) - 0.0018(d - 79.1)2. 
 
A similar method of estimation of usual blood pressure has been used previously in the 
analyses of the influence of blood pressure on vascular disease risk performed by the 
Prospective Studies Collaboration.3 
 
The following hazard ratios demonstrate how the use of a single blood pressure 
measurement or the average of 3 readings over 6 months would underestimate the 
relevance of SBP to vascular risk (among those who reported no previous history of 
cardiovascular disease and a baseline troponin-I ≤0.01ng/mL) compared to using the usual 
SBP described above. 
 
 Hazard ratio (95% CI) per 
10 mmHg higher SBP  
“Usual” SBP 1.29 (1.12-1.48)* 
Average SBP of 3 readings over 6 months 1.11 (1.05-1.16) 
Single baseline measure of SBP 1.08 (1.04-1.13) 
SBP = systolic blood pressure. *The hazard ratio quoted here for “usual” SBP differs to that 
quoted in Figure 3 as these analyses exclude participants with missing values of SBP at 2 or 
6 months. 
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Table S1: Baseline characteristics and laboratory measurements subdivided by self-reported 
history of prior cardiovascular disease and baseline troponin-I concentration 
 
 
Characteristic/measurement 
Self-reported history of previous cardiovascular disease 
and baseline troponin-I concentration 
No CVD  
CVD (n=1388) TnI≤0.01 (n=4070) TnI>0.01 (n=3208) 
Blood pressure    
Baseline systolic (mmHg) 136 (20) 142 (23) 141 (23) 
Baseline diastolic (mmHg) 80 (12) 79 (13) 76 (13) 
Usual systolic (mmHg) 135 (6) 136 (7) 136 (7) 
Usual diastolic (mmHg) 77 (5) 77 (5) 76 (5) 
Any antihypertensive medication 3405 (84%) 2722 (85%) 1194 (86%) 
Demographics    
Age at randomization (years) 59 (11) 64 (12) 67 (11) 
Men 2338 (57%) 2193 (68%) 910 (66%) 
Ethnicity    
White 2985 (73%) 2222 (69%) 1033 (74%) 
Black 73 (2%) 104 (3%) 41 (3%) 
Asian 908 (22%) 786 (25%) 272 (20%) 
Other 104 (3%) 96 (3%) 42 (3%) 
Education    
University 569 (14%) 307 (10%) 120 (9%) 
Secondary school 1377 (34%) 1016 (32%) 435 (31%) 
Vocational qualifications 891 (22%) 768 (24%) 366 (26%) 
Primary school or no formal education 651 (16%) 647 (20%) 287 (21%) 
Not specified 582 (14%) 470 (15%) 180 (13%) 
Current smoker 560 (14%) 387 (12%) 207 (15%) 
Prior disease    
Self-reported history of cardiovascular disease 0 (0%) 0 (0%) 1388 (100%) 
Troponin-I (ng/mL)    
0.01 4070 (100%) 0 (0%) 527 (38%) 
>0.01 to 0.03 0 (0%) 2502 (78%) 551 (40%) 
>0.03 to 0.1 0 (0%) 591 (18%) 186 (13%) 
>0.1 0 (0%) 115 (4%) 40 (3%) 
Diabetes 621 (15%) 859 (27%) 506 (36%) 
Renal status    
Not on dialysis 3187 (78%) 1731 (54%) 926 (67%) 
On dialysis 878 (22%) 1474 (46%) 460 (33%) 
Measurements    
CKD-EPI-estimated GFR (mL/min/1.73m²)*    
Mean (SD) 26.6 (13.3) 23.2 (12.0) 25.0 (13.0) 
60 49 (1%) 20 (1%) 13 (1%) 
30 to <60 1127 (28%) 426 (13%) 263 (19%) 
15 to <30 1375 (34%) 790 (25%) 411 (30%) 
<15 639 (16%) 498 (16%) 211 (15%) 
Urinary albumin:creatinine ratio (mg/g)*    
Median (IQR) 175 (37-645) 253 (60-896) 224 (49-979) 
<30 648 (16%) 267 (8%) 153 (11%) 
30 to 300 1159 (28%) 596 (19%) 293 (21%) 
>300 1152 (28%) 752 (23%) 363 (26%) 
Body-mass index (kg/m²) 27.0 (5.3) 27.0 (5.7) 27.4 (5.6) 
Treatment allocation    
Randomized to simvastatin plus ezetimibe 2014 (49%) 1630 (51%) 709 (51%) 
Mean (SD) or n (%) shown. GFR=glomerular filtration rate. CVD = self-reported history of cardiovascular disease. TnI=troponin-I. 
*For participants not on dialysis. Missing data as described in Table. 
Table S2: Additional baseline characteristics and laboratory measurements by tertiles of baseline blood pressure
Systolic blood pressure (SBP) Diastolic blood pressure (DBP)
Characteristic/measurement
Bottom third
(n=3123)
Middle third
(n=3015)
Top third
(n=3119) P value*
Bottom third
(n=3084)
Middle third
(n=3143)
Top third
(n=3019) P value†
Other demographics
Ethnicity <0.0001 0.0016
White 74% 74% 67% 74% 72% 69%
Black 3% 2% 3% 3% 3% 3%
Asian 20% 21% 26% 21% 23% 24%
Other 3% 3% 3% 3% 3% 4%
Education <0.0001 0.21
University 13% 12% 10% 11% 12% 12%
Secondary school 32% 34% 31% 32% 34% 33%
Vocational qualifications 22% 23% 24% 24% 22% 23%
Primary school or no formal education 17% 17% 21% 19% 18% 19%
Not specified 15% 14% 14% 15% 14% 14%
Current smoker 12% 13% 14% 0.07 13% 12% 14% 0.03
Medications
Number of antihypertensive medications <0.0001 0.01
None 19% 15% 13% 17% 17% 14%
One 26% 23% 23% 23% 25% 24%
Two 24% 26% 25% 23% 25% 28%
Three or more 30% 36% 38% 38% 33% 34%
Type of antihypertensive medication
ACE inhibitor or ARB 53% 55% 55% 0.12 54% 54% 55% 0.42
Beta blocker 36% 38% 39% 0.03 38% 36% 39% 0.03
Calcium channel blocker 32% 43% 48% <0.0001 40% 41% 43% 0.09
Diuretic 41% 41% 42% 0.50 45% 40% 39% <0.0001
Other co-medication
Antiplatelet therapy 23% 22% 23% 0.88 27% 21% 19% <0.0001
Oral anticoagulant therapy 4% 3% 3% 0.0021 4% 3% 3% 0.03
Erythropoiesis stimulating agent 26% 26% 29% 0.01 31% 26% 25% <0.0001
Sevelamer 9% 7% 8% 0.17 10% 7% 7% <0.0001
Table S2: Additional baseline characteristics and laboratory measurements by tertiles of baseline blood pressure
Systolic blood pressure (SBP) Diastolic blood pressure (DBP)
Characteristic/measurement
Bottom third
(n=3123)
Middle third
(n=3015)
Top third
(n=3119) P value*
Bottom third
(n=3084)
Middle third
(n=3143)
Top third
(n=3019) P value†
Other measurements
Body-mass index (kg/m²) 26.8 (5.4) 27.0 (5.4) 27.4 (5.4) 0.0005 27.1 (5.5) 27.2 (5.4) 27.0 (5.5) 0.44
Total cholesterol (mmol/L) 4.83 (1.15) 4.91 (1.15) 4.91 (1.16) 0.01 4.75 (1.17) 4.89 (1.14) 5.02 (1.16) <0.0001
LDL cholesterol (mmol/L) 2.74 (0.86) 2.80 (0.86) 2.78 (0.86) 0.02 2.68 (0.87) 2.78 (0.85) 2.86 (0.87) <0.0001
HDL cholesterol (mmol/L) 1.11 (0.33) 1.12 (0.33) 1.13 (0.33) 0.09 1.08 (0.33) 1.12 (0.33) 1.15 (0.33) <0.0001
Triglycerides (mmol/L) 2.31 (1.73) 2.34 (1.72) 2.32 (1.73) 0.81 2.38 (1.75) 2.28 (1.72) 2.31 (1.75) 0.07
Phosphate (mmol/L) 1.26 (0.44) 1.27 (0.44) 1.30 (0.44) 0.0008 1.30 (0.44) 1.26 (0.44) 1.27 (0.44) 0.0015
Hemoglobin (g/dL) 12.28 (1.66) 12.17 (1.65) 12.05 (1.64) <0.0001 11.90 (1.66) 12.24 (1.63) 12.37 (1.67) <0.0001
Albumin (g/L) 40.1 (3.7) 40.2 (3.7) 40.0 (3.7) 0.04 39.9 (3.8) 40.2 (3.7) 40.1 (3.8) 0.0028
C-reactive protein (mg/L) [geometric mean
(approximate SE)] 3.1 (0.1) 2.9 (0.1) 3.1 (0.1) 0.09 3.3 (0.1) 2.9 (0.1) 3.0 (0.1) 0.0004
Treatment allocation
Randomized to simvastatin plus ezetimibe 50% 51% 50% 0.52 50% 50% 50% 0.91
Mean (SD) or % shown, all characteristics adjusted for age, sex and ethnicity, with the exception of ethnicity. ACE=angiotensin-converting enzyme. ARB=angiotensin-II receptor blocker.
LDL=low-density lipoprotein. HDL=high-density lipoprotein. *P value for test of heterogeneity between SBP categories. †P value for test of heterogeneity beween DBP categories.
Table S3: Guideline recommendations for management of blood pressure in chronic kidney disease 
 
CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate; mGFR = measured glomerular filtration rate. 
* 
CKD defined using the National Kidney Foundation Kidney Disease 
Outcomes Quality Initiative (NFK KDOQI) definition as; either kidney damage (defined as pathological abnormalities or markers of damage, including abnormalities in blood or urine tests or imaging 
studies) or GFR <60 mL/min/1.73m
2
 for ≥3 months; 
† 
Microalbuminuria defined as urine albumin excretion ≥30-300 mg/d;
 ‡ 
Macroalbuminuria defined as urine albumin excretion >300 mg/d; 
§ 
Albuminuria defined as >30 mg/g at any age and at any level of GFR; 
║ 
If ≥70 years, treatment should be individualised, taking into consideration factors such as frailty, comorbidities and 
albuminuria; 
¶ 
CKD includes those with reduced renal function and/or the detection of elevated urinary excretion of albumin, staged according to eGFR; 
# 
Overt proteinuria defined as >300 mg/d; 
** 
Albuminuria defined as albumin:creatinine ratio ≥30 mg/mmol; 
††
 Albuminuria defined as albumin:creatinine ratio ≥70 mg/mmol; 
‡‡
 CKD defined as eGFR <60 mL/min/1.73 m
2
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Guideline  Blood pressure target, 
mmHg 
Target population and recommendation 
Kidney Disease Improving Global Outcomes (KDIGO, 2012)
1
 
 
≤140/90 CKD
*
 or diabetes without microalbuminuria
†
 
≤130/80 CKD
*
 or diabetes with micro
†
- or macroalbuminuria
‡ 
 
Eighth Joint National Committee (JNC-8, 2014)
2
 
 
 
<140/90 18-69 years and eGFR or mGFR <60 mL/min/1.73m
2
 with 
albuminuria
§
  
<150/90
 
eGFR <60 mL/min/1.73m
2 
and ≥70 years
║
, or CKD without 
albuminuria  
 
European Society of Hypertension (ESH) and the European Society of Cardiology (ESH-ESC, 2013)
3
  
 
<140/90 CKD
¶
  
<130/90 Overt proteinuria
# 
 
National Institute for Health and Clinical Excellence (NICE, 2014)
4
 
 
 
<140/90 Non-diabetic CKD
*
 without albuminuria
**
 
<130/80 CKD
*
 with albuminuria
††
 
CKD
*
 with diabetes 
 
American College of Cardiology Foundation and the American Heart Association (ACCF/AHA, 2011)
5
 
 
<130/80 CKD
‡‡
 in elderly patients with hypertension 
 
Canadian hypertension education program (CHEP, 2015)
6
 <140/90 Non-diabetic CKD
‡‡
 
<130/80 Diabetic CKD
‡‡
 
Figure S1: Causal diagram showing the assumed associations between baseline blood
pressure, outcomes and other characteristics
Non-renal
confounders*
BP at SHARP
randomization Outcomes
BP prior
to SHARP
(unobserved)
Antihypertensive use Renal function
and RRT status
Urinary albumin
excretion†
RRT=renal replacement therapy. *Age, sex, ethnicity, country, education, smoking status at
screening, previous cardiovascular disease, previous diabetes mellitus and body mass index.
Analyses were adjusted for the confounders enclosed by boxes in the causal diagram. No
adjustment was made for antihypertensive use as it was assumed that any effect on outcomes
was mediated through its effect on blood pressure.
†The a priori assumption was that urinary albumin excretion lies on the causal pathway between
blood pressure and vascular outcomes and is not a confounder, however sensitivity analyses
including adjustment for urinary albumin excretion were conducted.
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Figure S2: Mean blood pressure over follow−up in categories defined by
quintiles of baseline measurement
SBP=systolic blood pressure. DBP=diastolic blood pressure. Excludes 4161 participants with missing BP values at
any of the follow−up visits.
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Figure S3: Association between systolic blood pressure, diastolic blood pressure and pulse pressure and cardiovascular
events, subdivided by evidence of previous cardiovascular disease, for those less than 62 years old and 62 years or over
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therapy status, eGFR, body−mass index and treatment allocation are quoted (above squares) with numbers of events (below). Exclusions as per Table. *Hazard ratios per 10 mmHg higher usual
SBP/PP are presented for associations where there is no evidence of deviation from a log−linear relationship.
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Figure S4: Association between (A) systolic blood pressure, (C) diastolic blood pressure and (E) pulse pressure and
non−vascular mortality overall, and association between (B) systolic blood pressure, (E) diastolic blood pressure and
(F) pulse pressure and non−vascular mortality subdivided by evidence of previous cardiovascular disease
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